Peptide-guided nanoparticles for glioblastoma targeting

Säälik, Pille; Lingasamy, Prakash; Toome, Kadri; Mastandrea, Ignacio; Rousso-Noori, Liat; Tobi, Allan; Simón‐Gracia, Lorena; Hunt, Hedi; Paiste, Päärn; Kotamraju, Venkata Ramana; Bergers, Gabriele; Asser, Toomas; Rätsep, Tõnu; Ruoslahti, Erkki; Bjerkvig, Rolf; Friedmann‐Morvinski, Dinorah; Teesalu, Tambet

doi:10.1016/j.jconrel.2019.06.018

Cited by 74 publications

(40 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoparticle synthesis and functionalization. The iron oxide nanoworms (NWs) were prepared according to a published protocol by 8,26,27 . The aminated NWs were PEGylated using maleimide-5K-PEG-NH.…”

Section: Methodsmentioning

confidence: 99%

“…Peptides were coupled to NWs through a thioether bond between the thiol group of a cysteine residue added to the N-terminus of the peptide. The concentration of the NWs was determined by measuring the absorbance of NWs at 400 nm with a NanoDrop 2000c spectrophotometer (Thermo Scientific) 8,27 . Silver nanoparticles (AgNPs) were synthesized and functionalized as described 28 , CF647-N-hydroxysuccinimide-dye (NHS-dye) was conjugated to the PEG terminal amine groups, and biotinylated peptides were coated on the NeutrAvidin (NA) on the surface of the AgNPs.…”

Section: Methodsmentioning

confidence: 99%

“…Nuclei were counterstained with DAPI at 1 μg/ml. The coverslips were mounted on glass slides using Fluoromount-G (Electron Microscopy Sciences, PA, USA), imaged using confocal microscopy (Olympus FV1200MPE, Hamburg, Germany), and analyzed using the FV10 -ASW4.2 viewer, Imaris, and Fiji ImageJ software tools 8,27 . -NWs every other day for 10 injections.…”

Section: Cell Binding and Internalization Experiments U87-mg Ppc1mentioning

confidence: 99%

“…NWs were i.v. administered at 7.5 mg/kg NWs in mice bearing prostate cancer xenografts (PC3 s.c. tumors), or gliomas (s.c. U87-MG and orthotopic WT-GBM), both known to overexpress TNC-C and NRP-1 8,27 . After 5 h circulation, accumulation of PL3-NWs, but not control NWs, was observed in all 3 tumor models tested (Fig.…”

Section: Pl3 Peptide Interacts With Recombinant Tnc-c and Nrp-1 And Imentioning

confidence: 99%

See 3 more Smart Citations

Tumor-penetrating peptide for systemic targeting of Tenascin-C

Lingasamy

Tobi

Kurm

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Extracellular matrix in solid tumors has emerged as a specific, stable, and abundant target for affinityguided delivery of anticancer drugs. Here we describe the homing peptide that interacts with the C-isoform of Tenascin-C (TNC-C) upregulated in malignant tissues. TNC-C binding PL3 peptide (amino acid sequence: AGRGRLVR) was identified by in vitro biopanning on recombinant tnc-c. Besides tnc-C, PL3 interacts via its C-end Rule (CendR) motif with cell-and tissue penetration receptor neuropilin-1 (NRP-1). Functionalization of iron oxide nanoworms (NWs) and metallic silver nanoparticles (AgNPs) with PL3 peptide increased tropism of systemic nanoparticles towards glioblastoma (GBM) and prostate carcinoma xenograft lesions in nude mice (eight and five-fold respectively). Treatment of gliomabearing mice with proapoptotic PL3-guided NWs improved the survival of the mice, whereas treatment with untargeted particles had no effect. PL3-coated nanoparticles were found to accumulate in TNC-C and NRP-1-positive areas in clinical tumor samples, suggesting a translational relevance. The systemic tumor-targeting properties and binding of PL3-NPs to the clinical tumor sections, suggest that the PL3 peptide may have applications as a targeting moiety for the selective delivery of imaging and therapeutic agents to solid tumors.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Cell Binding and Internalization Experiments U87-mg Ppc1mentioning

confidence: 99%

Section: Pl3 Peptide Interacts With Recombinant Tnc-c and Nrp-1 And Imentioning

confidence: 99%

See 2 more Smart Citations

Tumor-penetrating peptide for systemic targeting of Tenascin-C

Lingasamy

Tobi

Kurm

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, the in vivo study showed that the targeting nano-delivery systems could accumulate within the tumor to a greater extent with remarkable decrease in the adverse effects of paclitaxel when compared with non-targeted nanosystems (Lei et al, 2019). Säälik et al (2019) investigated the effect of a novel penetrating peptide-guided nanoparticles that targets cell surface LinTT1, p32 for glioblastoma targeting. In this study, the coupling of LinTT1 to albumin-paclitaxel nano-delivery systems was achieved by sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate as a linker.…”

Section: Other Functionalized Drug Delivery Systems For Targeted Thermentioning

confidence: 99%

A Review of Nanotechnology for Targeted Anti-schistosomal Therapy

Adekiya

Kondiah

Choonara

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Schistosomiasis is one of the major parasitic diseases and second most prevalent among the group of neglected diseases. The prevalence of schistosomiasis may be due to environmental and socioeconomic factors, as well as the unavailability of vaccines for schistosomiasis. To date, current treatment; mainly the drug praziquantel (PZQ), has not been effective in treating the early forms of schistosome species. The development of drug resistance has been documented in several regions globally, due to the overuse of PZQ, rate of parasitic mutation, poor treatment compliance, co-infection with different strains of schistosomes and the overall parasite load. Hence, exploring the schistosome tegument may be a potential focus for the design and development of targeted anti-schistosomal therapy, with higher bioavailability as molecular targets using nanotechnology. This review aims to provide a concise incursion on the use of various advance approaches to achieve targeted anti-schistosomal therapy, mainly through the use of nano-enabled drug delivery systems. It also assimilates the molecular structure and function of the schistosome tegument and highlights the potential molecular targets found on the tegument, for effective specific interaction with receptors for more efficacious anti-schistosomal therapy.

show abstract

A Virus‐Mimicking pH‐Responsive Acetalated Dextran‐Based Membrane‐Active Polymeric Nanoparticle for Intracellular Delivery of Antitumor Therapeutics

Wannasarit

Wang

Figueiredo

et al. 2019

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Achieving cellular internalization and endosomal escape remains a major challenge for many antitumor therapeutics, especially macromolecular drugs. Viral drug carriers are reported for efficient intracellular delivery, but with limited choices of payloads. In this study, a novel polymeric nanoparticle (ADMAP) is developed, resembling the structure and functional features of a virus. ADMAP is synthesized by grafting endosomolytic poly(lauryl methacrylate-comethacrylic acid) on acetalated dextran. The endosomolytic polymer mimics the capsid protein for endosomal escape, and acetalated dextran resembles the viral core for accommodating payloads. After polymer synthesis, the subsequent controlled nanoprecipitation on a microfluidic device yields uniform nanoparticles with high encapsulation efficiency. At late endosomal pH (5.0), the ADMAP particles successfully destabilize endosomal membranes and release the drug payloads synergistically, resulting in a greater therapeutic efficacy compared with that of free anticancer drugs. Further conjugation of a tumorpenetrating peptide enhances the antitumor efficacy toward 3D spheroids and finally leads to spheroid disintegration. The unique structure along with the synergistic endosomal escape and drug release make ADMAP nanoparticles favorable for intracellular delivery of antitumor therapeutics.

show abstract

Peptide-guided nanoparticles for glioblastoma targeting

Cited by 74 publications

References 58 publications

Tumor-penetrating peptide for systemic targeting of Tenascin-C

Tumor-penetrating peptide for systemic targeting of Tenascin-C

A Review of Nanotechnology for Targeted Anti-schistosomal Therapy

A Virus‐Mimicking pH‐Responsive Acetalated Dextran‐Based Membrane‐Active Polymeric Nanoparticle for Intracellular Delivery of Antitumor Therapeutics

Contact Info

Product

Resources

About